Read More

Obseva Announced FDA Acceptance of NDA for Linzagolix

Obseva SA (NASDAQ: OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that the New Drug Application (NDA) for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women has been accepted

OBSV